Extended-Release Niacin with Laropiprant

HPS2-THRIVE trial

Among patients with atherosclerotic vascular disease, the addition of extended-release niacin–laropiprant to statin-based LDL cholesterol–lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events.  

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients — NEJM.

Leave a Reply